In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report). The company’s ...

In other recent news, Mersana Therapeutics has been making significant strides ... Continue reading in Investing.com ...

MRSN stock touches 52-week low at $0.56 amid market challenges Mersana Therapeutics Inc . (NASDAQ:MRSN) stock has reached a new 52-week low, trading at $0.56, as the biopharmaceutical company ...

and streamline your search for investment opportunities using Tipranks' Stock Screener Justin Zelin has given his Buy rating due to a combination of factors surrounding Mersana Therapeutics ...

Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ ... are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory ...

In other recent news, Mersana Therapeutics has been making notable strides in its ongoing clinical trials. The company's antibody-drug conjugates (ADCs), XMT-1660 and XMT-2056, have shown promising ...

Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ ... are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory ...

In other recent news, Mersana Therapeutics has been making significant strides in their clinical trials and financial performance. The company's Q3 2024 earnings call revealed a substantial ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...